Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CAPR Stock Price Chart Interactive Chart >
CAPR Price/Volume Stats
|Current price||$4.22||52-week high||$6.58|
|Prev. close||$4.25||52-week low||$2.81|
|Day high||$4.41||Avg. volume||123,060|
|50-day MA||$4.02||Dividend yield||N/A|
|200-day MA||$4.50||Market Cap||106.52M|
Capricor Therapeutics, Inc. (CAPR) Company Bio
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.
Most Popular Stories View All
CAPR Latest News Stream
|Loading, please wait...|
CAPR Latest Social Stream
View Full CAPR Social Stream
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchenne Muscular Dystrophy (DMD)- -Capricor to Host Webinar in Conjunction with Parent Project Muscular Dystrophy (PPMD) Today at 1:00 p.m. ET- SAN DIEGO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the d
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the C
Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor's proprietary StealthX exosome platform's therapeutic potential, generating two vaccine candidates (STX-S and STX-N). The vaccines independently and in combination (STX-S+N) induced a strong immune response against two SARS-CoV-2 proteins, spike and nucleocapsid. Results showed that this multivalent, protein-based vaccine candidate has the potential to achieve potent, lon
-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of a preclinical study highlighting new advances for its engineered exosome program. The dat
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CAPR Price Returns
Continue Researching CAPRWant to do more research on Capricor Therapeutics Inc's stock and its price? Try the links below:
Capricor Therapeutics Inc (CAPR) Stock Price | Nasdaq
Capricor Therapeutics Inc (CAPR) Stock Quote, History and News - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Stock Price and Basic Information | MarketWatch